

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 5

Complete if Known

Application Number	09/767370
Filing Date	01/23/2001
First Named Inventor	Browning, Jeffrey
Group Art Unit	1642
Examiner Name	A. Holleran
Attorney Docket Number	A054 US

TECH CENTER 1600/2900
JAN 14 2002

RECEIVED

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CY	CA	Aggarwal et al., 1996, Eur. Cytokine Netw., 7:93-124, "Tumor necrosis factors: Developments during the last decade"	
CY	CB	Alderson, Mark R., 1994, Eur. J. Immunol., 24:2219-2227, "Molecular and biological characterization of human 4-1BB and its ligand"	
CY	CC	Ashkenazi, Avi et al., 1991, Proc. Natl. Acad. Sci., 88:10535-10539, "Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin"	
CY	CD	Banner, David W. et al., 1993, Cell, 73:431-445, "Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNFbeta Complex: Implications for TNF Receptor Activation"	
CY	CE	Baum, Peter et al., 1994, The EMBO Journal, 13:3992-4001, "Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1 regulated protein gp34"	
CY	CF	Flier, Jeffrey S., et al., 1996, The New England Journal of Medicine, 334:1717-1725, "THE TUMOR NECROSIS FACTOR LIGAND AND RECEPTOR FAMILIES"	
CY	CG	Browning et al., 1995, The J. of Immunology, 154:33-46, "Characterization of Surface Lymphotoxin Forms Use of Specific Monoclonal Antibodies and Soluble Receptors"	
CY	CH	Browning et al., 1996, The J. of Biological Chemistry, 271:8618-8626, "Preparation and Characterization of Soluble Recombinant Heterotrimeric Complexes of Human Lymphotoxins alpha and beta"	
CY	CI	Browning et al., 1996, J. Exp. Med., 183:867-878, "Signaling through the Lymphotoxin Beta Receptor Induces the Death of Some Adenocarcinoma Tumor Lines"	
CY	CJ	Bucay et al., 1998, Genes and Development, 12:1260-1268, "osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification"	
CY	CK	Chaplin et al., 1998, Current Opinion in Immunology, 10:289-297, "Cytokine regulation of secondary lymphoid organ development"	

Examiner Signature	<u>Christoph H Y</u>	Date Considered	<u>7-29-02</u>
--------------------	----------------------	-----------------	----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ☐

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 5

Complete if Known

Application Number	09/767370
Filing Date	01/23/2001
First Named Inventor	Browning, Jeffrey
Group Art Unit	1642
Examiner Name	A. Holleran
Attorney Docket Number	A054 US

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CY	CL	Chicheportiche et al., 1997, J. of Biological Chemistry, 272:32401-32410, "TWEAK, a New Secreted Ligand in the Tumor Necrosis Factor Family That Weakly Induces Apoptosis"	
CY	CM	Corcoran et al., 1994, Eur. J. Biochem., 223:831-840, "Characterization of ligand binding by the human p55 tumour-necrosis-factor receptor"	
CY	CN	Crowe et al., 1994, Science, 264:707-710, "A Lymphotoxin-beta-Specific Receptor"	
CY	CO	Degli-Esposti et al., 1997, J. of Immunology, 158:1756-1762, "Activation of the Lymphotoxin Beta Receptor by Cross-Linking Induces Chemokine Production and growth arrest in A375 melanoma cells"	
CY	CP	Eason et al., 1996, Transplantation, 61:224-228, "EVALUATION OF RECOMBINANT HUMAN SOLUBLE DIMERIC TUMOR NECROSIS FACTOR RECEPTOR FOR PREVENTION OF OKT3-ASSOCIATED ACUTE CLINICAL SYNDROME"	
CY	CQ	Eggermont et al., 1996, J. of Clinical Oncology, 14:2653-2665, "Isolated Limb Prefusion With High-Dose Tumor Necrosis Factor-alpha in Combination With Interferon-gamma and Melphalan for Nonresectable Extremity Soft Tissue Sarcomas: A Multicenter Trial"	
CY	CR	Fanslow et al., 1992, J. of Immunology, 149:655-660, "SOLUBLE FORMS OF CD40 INHIBIT BIOLOGIC RESPONSES OF HUMAN B CELLS"	
CY	CS	Feldman et al., 1997, Advances in Immunology, 64:283-350, "Anti-Tumor Necrosis Factor-alpha Therapy of Rheumatoid Arthritis"	
CY	CT	Goodwin et al., 1993, Cell, 73:447-456, "Molecular and Biological Characterization of a Ligand for CD27 Defines a New Family of Cytokines with Homology to Tumor Necrosis Factor"	
CY	CU	Green et al., 1997, Proc. Natl. Acad. Sci., 94:5986-5990, "Fas-ligand: Privilege and peril"	
CY	CV	Harrop et al., 1998, J. of Biological Chemistry, 273:27548-27556, "Herpesvirus Entry Mediator Ligand (HVEM-L), a Novel Ligand for HVEM/TR2, Stimulates Proliferation of T Cells and Inhibits HT29 Cell Growth"	

Examiner Signature	Christoph H Yan	Date Considered	7-29-02
--------------------	-----------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


RECEIVED

JAN 14 2002

TECH CENTER 1600/2900

Please type a plus sign (+) inside this box → 

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **4** of **5**

Complete if Known

Application Number	09/767370
Filing Date	01/23/2001
First Named Inventor	Browning, Jeffrey
Group Art Unit	1642
Examiner Name	A. Holleran
Attorney Docket Number	A054 US

TECH CENTER 1600/2900

JAN 14 2002

RECEIVED

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CY	CW	Hudee et al., 1999, Gene Therapy, 6:939-943, "Activated polyamidoamine dendrimers, a non-viral vector for gene transfer to the corneal endothelium"	
CY	CX	Mackay et al., 1998, Gastroenterology, 115:1464-1475, "Both the Lymphotoxin and Tumor Necrosis Factor Pathways Are Involved in Experimental Murine Models of Colitis"	
CY	CY	Mackay et al., 1998, Nature, 395:26-27, "Turning off follicular dendritic cells"	
CY	CZ	Mackay et al., 1997, Eur. J. Immunol., 27:2033-2042, "Lymphotoxin but not tumor necrosis factor functions to maintain splenic architecture and humoral responsiveness in adult mice"	
CY	CCA	Marsters et al., 1992, The J. of Biological Chem., 267:5747-5750, "Identification of Cysteine-rich Domains of the Type I Tumor Necrosis Factor Receptor Involved in Ligand Binding"	
CY	CCB	Mauri et al., 1998, Immunity, 8:21-30, "LIGHT, a New Member of the TNF Superfamily, and Lymphotoxin alpha Are Ligands for Herpesvirus Entry Mediator"	
CY	CCD	Mohler et al., 1993, J. of Immunology, 151:1548-1561, "Soluble Tumor Necrosis Factor (TNF) Receptors Are Effective Therapeutic Agents in Lethal Endotoxemia and Function Simultaneously as Both TNF Carriers and TNF Antagonists"	
CY	CCD	Naismith et al. 1996, J. of Molecular Recognition, 9:113-117, "Seeing Double: Crystal Structures of the Type I TNF Receptor"	
CY	CCE	Rennert et al. 1996, J. Exp. Med., 184:1999-2006, "Surface Lymphotoxin alpha/Beta Complex Is Required for the Development of Peripheral Lymphoid Organs"	
CY	CCF	Rennert et al., 1997, International Immunology, 9:1627-1639, "Selective disruption of lymphotoxin ligands reveals a novel set of mucosal lymph nodes and unique effects of lymph node cellular organization"	
CY	CCG	Rudikoff et al., 1986, Proc. Natl. Acad. Sci., 83:7875-7878, "Functional antibody lacking a variable-region disulfide bridge"	

Examiner Signature	<i>Christopher H Ye</i>	Date Considered	7-29-02
--------------------	-------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 5

Complete if Known

Application Number	09/767370
Filing Date	01/23/2001
First Named Inventor	Browning, Jeffrey
Group Art Unit	1642
Examiner Name	A. Holleran
Attorney Docket Number	A054 US

TECH CENTER 1604/2900

JAN 14 2002

RECEIVED

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ²	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CY	CCJ	Simonet et al., 1997, Cell, 89:309-319, "Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density"	
CY	CCJ	Smith et al., 1994, Cell, 76:959-962, "The TNF Receptor Superfamily of Cellular and Viral Proteins: Activation, Costimulation, and Death"	
CY	CCJ	Smith et al., 1993, Cell, 73:1349-1360, "CD30 Antigen, a Marker for Hodgkin's Lymphoma, Is a Receptor Whose Ligand Defines an Emerging Family of Cytokines with Homology to TNF"	
CY	CCJ	Suda et al., 1993, Cell, 75:1169-1178, "Molecular Cloning and Expression of the Fas Ligand, a Novel Member of the Tumor Necrosis Factor Family"	
CY	CCJ	Van Dullemen et al., 1995, Gastroenterology, 109:129-135, "Treatment of Crohn's Disease With Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2)"	
CY	CCJ	Ware et al., 1995, Current Topics in Microbiology and Immunology, 198:175-218, "The Ligands and receptors of the Lymphotoxin System"	
CY	CCJ	Williams et al., 1995, Immunology, 84:433-439, "Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4"	
CY	CCJ	Loetscher, Hansruedi et al., 1991, J. of Biological Chemistry, 266:18324-18329, "Recombinant 55-kDa Tumor Necrosis Factor (TNF) Receptor"	
CY	CCJ	Weickert et al., 1997, Applied and Environmental Microbiology, 63:4313-4320, "Stabilization of Apoglobin by Low Temperature Increases Yield of Soluble Recombinant Hemoglobin in Escherichia coli"	

Examiner Signature	Christopher H Y	Date Considered	7-29-02
--------------------	-----------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.